|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Mirum Pharmaceuticals, Inc. (MIRM) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
53,602,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Mirum Pharmaceuticals is a biopharmaceutical company focused on the identification, acquisition, development and commercialization of therapies for rare and orphan diseases. Co.'s focus is the development and commercialization of LIVMARLI® (maralixibat) oral solution (Livmarli) and volixibat. Livmarli is an oral solution approved as a once daily medicine for cholestatic pruritus in patients with Alagille syndrome one year of age and older. Co.'s second product candidate, volixibat, an oral, minimally-absorbed agent designed to inhibit ileal bile acid transporter, for the treatment of adult patients with cholestatic liver diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
4,000 |
4,000 |
175,963 |
175,963 |
Total Buy Value |
$101,200 |
$101,200 |
$4,703,025 |
$4,703,025 |
Total People Bought |
1 |
1 |
2 |
2 |
Total Buy Transactions |
2 |
2 |
8 |
8 |
Total Shares Sold |
4,303 |
26,974 |
69,916 |
431,922 |
Total Sell Value |
$111,017 |
$737,972 |
$1,983,116 |
$9,495,201 |
Total People Sold |
1 |
5 |
6 |
8 |
Total Sell Transactions |
1 |
12 |
21 |
30 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Odonnell Niall |
Director |
|
2022-11-15 |
4 |
S |
$19.69 |
$1,846,022 |
I/I |
(93,770) |
1,621,118 |
|
- |
|
Odonnell Niall |
Director |
|
2022-11-14 |
4 |
S |
$19.60 |
$629,423 |
I/I |
(32,109) |
1,714,888 |
|
- |
|
Odonnell Niall |
Director |
|
2022-11-11 |
4 |
S |
$19.99 |
$3,481,410 |
I/I |
(174,121) |
1,746,997 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2022-11-10 |
4 |
A |
$17.05 |
$5,542 |
D/D |
325 |
30,011 |
|
- |
|
Vig Pamela |
Head of Research & Development |
|
2022-11-10 |
4 |
A |
$17.05 |
$11,254 |
D/D |
660 |
21,902 |
|
- |
|
Peetz Christopher |
President and CEO |
|
2022-11-10 |
4 |
A |
$17.05 |
$835 |
D/D |
49 |
69,576 |
|
- |
|
Longpre Lara |
Chief Development Officer |
|
2022-11-10 |
4 |
A |
$17.05 |
$1,398 |
D/D |
82 |
96,534 |
|
- |
|
Radovich Peter |
Chief Operating Officer |
|
2022-11-10 |
4 |
A |
$17.05 |
$4,979 |
D/D |
292 |
23,692 |
|
- |
|
Deerfield Healthcare Innovations Fund, L.p. |
* Possible Member of 10% Group |
|
2022-06-06 |
4 |
S |
$24.47 |
$962,256 |
I/I |
(38,478) |
1,540,190 |
|
- |
|
Radovich Peter |
Chief Operating Officer |
|
2022-05-10 |
4 |
A |
$13.57 |
$15,859 |
D/D |
1,169 |
23,400 |
|
- |
|
Longpre Lara |
Chief Development Officer |
|
2022-05-10 |
4 |
A |
$13.57 |
$19,725 |
D/D |
1,454 |
96,452 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2022-05-10 |
4 |
A |
$13.57 |
$15,262 |
D/D |
1,125 |
29,686 |
|
- |
|
Vig Pamela |
Head of Research & Development |
|
2022-05-10 |
4 |
A |
$13.57 |
$10,948 |
D/D |
807 |
21,242 |
|
- |
|
Peetz Christopher |
President and CEO |
|
2022-05-10 |
4 |
A |
$13.57 |
$20,349 |
D/D |
1,500 |
69,527 |
|
- |
|
Peetz Christopher |
President and CEO |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
68,027 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
28,561 |
|
- |
|
Radovich Peter |
Chief Operating Officer |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
22,231 |
|
- |
|
Vig Pamela |
Chief Scientific Officer |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,435 |
|
- |
|
Longpre Lara |
Chief Development Officer |
|
2022-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
94,998 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2021-11-26 |
4 |
B |
$13.90 |
$10,425 |
D/D |
750 |
18,561 |
2.74 |
- |
|
Clements Ian |
Chief Financial Officer |
|
2021-11-24 |
4 |
B |
$14.40 |
$10,080 |
D/D |
700 |
17,811 |
2.74 |
- |
|
Vig Pamela |
Chief Scientific Officer |
|
2021-11-10 |
4 |
A |
$13.52 |
$10,380 |
D/D |
768 |
10,435 |
|
- |
|
Clements Ian |
Chief Financial Officer |
|
2021-11-10 |
4 |
A |
$13.52 |
$6,190 |
D/D |
458 |
17,111 |
|
- |
|
Tucker Edwin Jonathan |
Chief Medical Officer |
|
2021-11-10 |
4 |
A |
$13.52 |
$946 |
D/D |
70 |
45,838 |
|
- |
|
Radovich Peter |
Chief Operating Officer |
|
2021-11-10 |
4 |
A |
$13.52 |
$12,947 |
D/D |
958 |
12,231 |
|
- |
|
191 Records found
|
|
Page 4 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|